Integration of PARP-inhibitors in ovarian cancer therapy

Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unp...

Descripción completa

Detalles Bibliográficos
Autores principales: Pietragalla, Antonella, Ciccarone, Francesca, Nero, Camilla, Scambia, Giovanni, Lorusso, Domenica, Daniele, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400691/
https://www.ncbi.nlm.nih.gov/pubmed/36046198
http://dx.doi.org/10.37349/etat.2020.00011
_version_ 1784772797638115328
author Pietragalla, Antonella
Ciccarone, Francesca
Nero, Camilla
Scambia, Giovanni
Lorusso, Domenica
Daniele, Gennaro
author_facet Pietragalla, Antonella
Ciccarone, Francesca
Nero, Camilla
Scambia, Giovanni
Lorusso, Domenica
Daniele, Gennaro
author_sort Pietragalla, Antonella
collection PubMed
description Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients.
format Online
Article
Text
id pubmed-9400691
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Open Exploration
record_format MEDLINE/PubMed
spelling pubmed-94006912022-08-30 Integration of PARP-inhibitors in ovarian cancer therapy Pietragalla, Antonella Ciccarone, Francesca Nero, Camilla Scambia, Giovanni Lorusso, Domenica Daniele, Gennaro Explor Target Antitumor Ther Review Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients. Open Exploration 2020 2020-06-29 /pmc/articles/PMC9400691/ /pubmed/36046198 http://dx.doi.org/10.37349/etat.2020.00011 Text en © The Author(s) 2020. https://creativecommons.org/licenses/by/4.0/This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Pietragalla, Antonella
Ciccarone, Francesca
Nero, Camilla
Scambia, Giovanni
Lorusso, Domenica
Daniele, Gennaro
Integration of PARP-inhibitors in ovarian cancer therapy
title Integration of PARP-inhibitors in ovarian cancer therapy
title_full Integration of PARP-inhibitors in ovarian cancer therapy
title_fullStr Integration of PARP-inhibitors in ovarian cancer therapy
title_full_unstemmed Integration of PARP-inhibitors in ovarian cancer therapy
title_short Integration of PARP-inhibitors in ovarian cancer therapy
title_sort integration of parp-inhibitors in ovarian cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400691/
https://www.ncbi.nlm.nih.gov/pubmed/36046198
http://dx.doi.org/10.37349/etat.2020.00011
work_keys_str_mv AT pietragallaantonella integrationofparpinhibitorsinovariancancertherapy
AT ciccaronefrancesca integrationofparpinhibitorsinovariancancertherapy
AT nerocamilla integrationofparpinhibitorsinovariancancertherapy
AT scambiagiovanni integrationofparpinhibitorsinovariancancertherapy
AT lorussodomenica integrationofparpinhibitorsinovariancancertherapy
AT danielegennaro integrationofparpinhibitorsinovariancancertherapy

Ejemplares similares